Seminars in Oncology
Volume 30, Issue 5 , Pages 567-586 , October 2003

Predicting clinical end points: treatment nomograms in prostate cancer

  • Christopher J Di Blasio

      Affiliations

    • Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Audrey C Rhee

      Affiliations

    • Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Daniel Cho

      Affiliations

    • Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Peter T Scardino

      Affiliations

    • Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • ,
  • Michael W Kattan

      Affiliations

    • Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    • Corresponding Author InformationAddress reprint requests to Michael W. Kattan, PhD, Departments of Urology and Biostatistics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA

References 

  1. Jemal A, Murray T, Samuels A, et al.  Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5–26
  2. Han M, Partin AW, Piantadosi S, et al.  Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001;166:416–419
  3. Ohori M, Wheeler TM, Kattan MW, et al.  Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995;154:1818–1824
  4. Gerber GS, Thisted RA, Scardino PT, et al.  Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA. 1996;276:615–619
  5. Pound CR, Partin AW, Epstein JI, et al.  Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am. 1997;24:395–406
  6. Trapasso JG, de Kernion JB, Smith RB, et al.  The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol. 1994;152:1821–1825
  7. Bagshaw MA, Cox RS, Hancock SL. Control of prostate cancer with radiotherapy (Long-term results). J Urol. 1994;152:1781–1785
  8. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol. 1995;154:456–459
  9. Ragde H, Blasko JC, Grimm PD, et al.  Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 1997;80:442–453
  10. Chodak GW, Thisted RA, Gerber GS, et al.  Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330:242–248
  11. Albertsen PC, Fryback DG, Storer BE, et al.  Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274:626–631
  12. Kattan MW, Scardino PT. Prediction of progression (Nomograms of clinical utility). Clin Prostate Cancer. 2002;1:90–96
  13. Wilt TJ, Brawer MK. The Prostate Cancer Intervention Versus Observation Trial (A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer). J Urol. 1994;152:1910–1914
  14. Cowen ME, Miles BJ, Cahill DF, et al.  The danger of applying group-level utilities in decision analyses of the treatment of localized prostate cancer in individual patients. Med Decis Making. 1998;18:378–380
  15. Ross PL, Scardino PT, Kattan MW. A catalog of prostate cancer nomograms. J Urol. 2001;165:1562–1568
  16. Ross PL, Gerigk C, Gonen M, et al.  Comparisons of nomograms and urologists’ predictions in prostate cancer. Semin Urol Oncol. 2002;20:82–88
  17. Hogarth R. Judgment and Choice (The Psychology of Decision). (ed 2).. New York, NY: Wiley; 1987; p 311
  18. Kattan M. Expert systems in medicine. In:  Smelser NJ,  Baltes PB editor. International Encyclopedia of the Social Behavioral Sciences. New York, NY: Elsevier; 2001;p. 5135–5139
  19. Meehl PE. Causes and effects of my disturbing little book. J Pers Assess. 1986;50:370–375
  20. Partin AW, Yoo J, Carter HB, et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110–114
  21. Partin AW, Kattan MW, Subong EN, et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277:1445–1451
  22. Partin AW, Mangold LA, Lamm DM, et al.  Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millenium. Urology. 2001;58:843–848
  23. Kattan MW, Eastham JA, Stapleton AM, et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–771
  24. Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499–1507
  25. Kattan MW, Zelefsky MJ, Kupelian PA, et al.  Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352–3359
  26. Kattan MW, Potters L, Blasko JC, et al.  Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology. 2001;58:393–399
  27. Kattan MW, Reuter V, Motzer RJ, et al.  A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63–67
  28. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20:791–796
  29. Smaletz O, Scher HI, Small EJ, et al.  Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20:3972–3982
  30. Halabi S, Small EJ, Kantoff P, et al.  A prognostic model for predicting overall survival in men with hormone refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232–1237
  31. Hull GW, Rabbani F, Abbas F, et al.  Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167:528–534
  32. Zelefsky MJ, Fuks Z, Hunt M, et al.  High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876–881
  33. Kattan MW, Stapleton AM, Wheeler TM, et al.  Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer. 1997;79:528–537
  34. Critz FA, Williams WH, Holladay CT, et al.  Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology. 1999;54:968–971
  35. Hanks GE, Hanlon AL, Schultheiss TE, et al.  Conformal external beam treatment of prostate cancer. Urology. 1997;50:87–92
  36. Amling CL, Bergstralh EJ, Blute ML, et al.  Defining prostate specific antigen progression after radical prostatectomy (What is the most appropriate cut point?). J Urol. 2001;165:1146–1151
  37. Zincke H, Oesterling JE, Blute ML, et al.  Long term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol. 1994;152:1850–1857
  38. Catalona WJ, Smith DS. Five-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152:1837–1842
  39. American Society for Therapeutic Radiology and Oncology Consensus Panel . Consensus statement. Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  40. Kattan MW, Fearn PA, Leibel S, et al.  The definition of biochemical failure in patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2000;48:1469–1474
  41. Hanlon AL, Hanks GE. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients deomnstrates its usefullness and robustness. Int J Radiat Oncol Biol Phys. 2000;46:559–566
  42. Zagars GK, Geara FB, Pollack A, et al.  The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy. Cancer. 1994;73:1904–1912
  43. Graefen M, Karakiewicz PI, Cagiannos I, et al.  International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002;20:3206–3212
  44. Graefen M, Karakiewicz PI, Cagiannos I, et al.  A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol. 2002;7:141–146
  45. Graefen M, Karakiewicz PI, Cagiannos I, et al.  Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol. 2002;20:951–956
  46. Schellhammer PF, Cockett A, Boccon-Gibod L, et al.  Assessment of endpoints for clinical trials for localized prostate cancer. Urology. 1997;49:27–38
  47. Middleton RG, Thompson IM, Austenfeld MS, et al.  Prostate Cancer Clinical Guidelines Panel Summary report on the managment of clinically localized prostate cancer. The American Urological Association. J Urol. 1995;154:2144–2148
  48. Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients (Preoperative application in prostate cancer). Curr Opin Urol. 2003;13:111–116
  49. D’Amico AV, Whittington R, Malkowicz SB, et al.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  50. D’Amico AV, Whittington R, Malkowicz SB, et al.  A multivariate analysis of clinical and pathologic factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol. 1995;154:131–138
  51. Potters L, Cha C, Oshinsky G, et al.  Risk profiles to predict PSA-relapse free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am. 1999;5:301–306
  52. Shipley WU, Thames HD, Sandler HM, et al.  Radiation therapy for clinically localized prostate cancer (A multi-institutional pooled analysis). JAMA. 1999;281:1598–1604
  53. Kattan MW, Eastham JA. Algorithms for PSA recurrence after treatment of localized prostate cancer. Clin Prostate Cancer. 2003;1:221–226
  54. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models (Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors). Stat Med. 1996;15:361–387
  55. Mazumdar M, Fazzari M, Panageas KS. A standardization method to adjust for the effect of patient selection in phase II clinical trials. Stat Med. 2001;20:883–892
  56. Antman EM, Cohen M, Bernink PJ, et al.  The TIMI risk score for unstable angina/non-ST elevation MI (A method for prognostication and therapeutic decision making). JAMA. 2000;284:876–878
  57. Stamey TA, Yemoto CM, McNeal JE. Prostate cancer is highly predictable (A prognostic equation based on all morphological variables in radical prostatectomy specimens). J Urol. 2000;163:1155–1160
  58. Bauer JJ, Connelly RR, Seterhenn IA, et al.  Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol. 1998;159:929–933
  59. Calvanese CB, Kahane H, Carlson GD. A presurgical staging of prostate cancer. Infect Urol. 1999;12:22–28
  60. Harrell FE, Margolis PA, Gove S. Development of a clinical prediction model for an ordinary outcome: The World Health Organization multicenter study of clinical signs and etiological agents of pneumonia, sepsis, and meningitis in young infants. WHO/ARI Young Infant Multicenter Study Group. Stat Med. 1998;17:909–944
  61. Harrell FE, Lee KL, Califf RM, et al.  Regression modelling strategies for improved prognostic prediction. Stat Med. 1984;3:143–152
  62. Begg CB, Cramer ID, Venkatraman FS. Comparing tumour staging and grading systems (A case study and a review of the issues, using thymoma as a model). Stat Med. 2000;19:1997–2014
  63. Cantor SB, Kattan MW. Determining the area under the ROC curve for a binary diagnostic test. Med Decis Making. 2000;20:468–470
  64. Harrell FE, Califf RM, Pryor DB, et al.  Evaluating the yield of medical tests. JAMA. 1982;247:2543–2546
  65. Snow PB, Smith DS, Catalona WJ. Artificial neural networks in the diagnosis and prognosis of prostate cancer (A pilot study). J Urol. 1994;152:1923–1926
  66. Burke HB, Goodman PH, Rosen DB. Artificial neural networks improve the accuracy of cancer survival prediction. Cancer. 1997;79:857–862
  67. Picard RR, Berk KN. Data splitting. Am Stat. 1990;44:140–147
  68. Efron B. Estimating the error rate of a prediction rule (Improvement on cross-validation). J Am Stat Assoc. 1983;78:316–331
  69. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1993;
  70. Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. Am Stat. 1983;37:36–48
  71. Chan TY, Partin AW, Walsh PC, et al.  Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology. 2000;56:823–827
  72. Yan Y, Carvalhal GF, Catalona WJ, et al.  Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 2000;88:1122–1130
  73. Wheeler TM, Dillioglugil O, Kattan MW, et al.  Clinical and pathologic significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 1998;29:856–862
  74. American Joint Committee on Cancer . AJCC Cancer Staging Manual. (ed 4).. Philadelphia, PA: Lippincott-Raven; 1992;
  75. Perez CA, Michalski JM, Purdy JA, et al.  Three-dimensional conformal radiation therapy (3-D CRT), brachytherapy, and new therapeutic modalities. Rays. 2000;25:331–343
  76. Bolla M, Gonzalez D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  77. Hilaris BS. Brachytherapy in cancer of the prostate (An historical perspective). Semin Surg Oncol. 1997;13:399–405
  78. Giles GM, Brady LW. 125-Iodine implantation after lymphadenectomy in early carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1986;12:2117–2125
  79. Zelefsky MJ, Whitmore WF. Long-term results of retropubic permanent 125-iodine implantation of the prostate for clinically localized prostatic cancer. J Urol. 1997;158:23–29
  80. Stokes SH, Real JD, Adams PW, et al.  Transperineal ultrasound-guided radioactive seed inplantation for organ-confined carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1997;37:337–341
  81. Ragde H, Korb LJ, Elgamal A, et al.  Modern prostate brachytherapy (Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up). Am Cancer Soc. 2000;89:135–141
  82. Zelefsky MJ, Hollister T, Raben A, et al.  Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2000;47:1261–1266
  83. D’Amico AV, Vogelzang NA. Prostate brachytherapy (Increasing demand for the procedure despite the lack of standardized quality assurance and long-term outcome data). Cancer. 1999;86:1632–1634
  84. Fleming ID, Cooper JS, Henson DE, et al.  AJCC Cancer Staging Manual. (ed 5).. Philadelphia, PA: Lippincott-Raven; 1997;
  85. Hu JC, Gold KF, Pashos CL, et al.  Role of surgeon volume in radical prostatectomy outcomes. J Clin Oncol. 2003;21:401–405
  86. Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med. 1997;12:299–305
  87. Scher HI, Heller G. Clinical states in prostate cancer (Toward a dynamic model of disease progression). Urology. 2000;55:323–327
  88. Eastham JA, Kattan MW, Scardino PT. Nomograms as predictive models. Semin Urol Oncol. 2002;20:108–115
  89. Holmberg L, Bill-Axelson A, Helgesen F, et al.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med. 2002;347:781–789
  90. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma (Analysis of 938 patients irradiated in the prostate specific antigen era). Cancer. 1997;79:1370–1380
  91. Ragde H, Elgamal AA, Snow PB, et al.  Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 1998;83:989–1001
  92. Grado GL, Larson TR, Balch CS, et al.  Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys. 1998;44:289–298
  93. D’Amico AV, Cote K, Loffredo M, et al.  Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol. 2002;20:4567–4573
  94. Dillioglugil O, Leibman BD, Leibman NS, et al.  Risk factors for complications and morbidity after radical retropubic prostatectomy. J Urol. 1997;157:1760–1767
  95. Lepor H, Nieder AM, Ferrandino MN. Intraoperative and postoperative complications of radical retropubic prostatectomy in a consecutive series of 1,000 cases. J Urol. 2001;166:1729–1733
  96. Steineck G, Helgesen F, Adolfsson J, et al.  Quality of life after radical prostatectomy or watchful waiting. N Engl J Med. 2002;347:790–796
  97. Nguyen LN, Pollack A, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose-response study (Results of a self-assessment questionairre). Urology. 1998;51:991–997
  98. Gelblum DY, Potter L, Ashley R, et al.  Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. Int J Radiat Oncol Biol Phys. 1999;45:59–67
  99. Madalinska JB, Essink-Bot ML, de Koning HJ, et al.  Health-related quality of life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol. 2001;19:1619–1628
  100. Wei JT, Dunn RL, Sandler HM, et al.  Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20:557–566
  101. Rabbani F, Stapleton AM, Kattan MW, et al.  Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000;164:1929–1934
  102. Zelefsky MJ, Cowen D, Fuks Z, et al.  Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 1999;85:2460–2468
  103. Potters L, Torre T, Fearn P, et al.  Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2001;50:1235–1242
  104. Gelblum DY, Potters L. Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:119–124

PII: S0093-7754(03)00351-8

doi: 10.1016/S0093-7754(03)00351-8

Seminars in Oncology
Volume 30, Issue 5 , Pages 567-586 , October 2003

Article Tools

* Image Usage & Resolution